Latest BPH Stories

CHARLOTTESVILLE, Va., Feb. 22, 2011 /PRNewswire-USNewswire/ -- The Focused Ultrasound Surgery Foundation has released a special men's heath update in its February 2011 online newsletter. According to the update, tremendous progress is being made in developing new minimally-invasive and highly precise treatments for two conditions that afflict millions of men worldwide - prostate cancer and benign prostatic hyperplasia (BPH). By offering increased precision, the new treatments are expected...

Researchers from Boston University School of Medicine (BUSM), in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors (5a-RIs), while improving urinary symptoms in patients with benign prostatic hyperplasia (BPH) and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction (ED), ejaculatory dysfunction and potential depression. These findings, which...

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better."We don't know the mechanism, but the results suggest to us that lowering cholesterol has the potential to reduce BPH in men," says senior author Keith Solomon, PhD, a...

MINNETONKA, Minn., Oct. 4 /PRNewswire-FirstCall/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced that eight GreenLight HPS® laser consoles have been acquired for public hospitals in the Australian states of Victoria and Queensland. The laser technology will treat patients with Benign Prostatic Hyperplasia (BPH), a non cancerous enlargement of the prostate experienced by 50...

VANCOUVER, Sept. 29 /PRNewswire-FirstCall/ - Protox Therapeutics Inc. (the "Company" or "Protox") (TSX: PRX), a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement. Under the Investment Agreement, Warburg Pincus Private Equity X, L.P. and Warburg Pincus X Partners, L.P. (together "Warburg...

NEVILLEWOOD, Pa., July 12 /PRNewswire/ -- A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH). BPH, also known as an enlarged prostate, is the most common benign proliferative disorder in men, affecting more than 50 percent of men over the age of 70. Symptoms include...

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic. The researchers presented their results today at the annual meeting of the American Urological Association.Overall, results show:    * Urinary incontinence was...

BEIJING, April 29, /PRNewswire/ -- Realton Corporation, a pioneer in developing diode-pumped laser systems initially targeted to treat enlarged prostate, today announced the closing of its Series B financing co-led by OrbiMed Advisors and China Healthcare Partnership (CHP, a fund under Martin Currie Asset Management Group). Existing investor CSV Capital Partners will also participate in the financing. The financing will be used primarily to enhance Realton's marketing and distribution...

All amounts are in U.S. dollars QUEBEC CITY, March 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009. 2009 Highlights Perifosine - Updated positive Phase 2 efficacy and safety data as well as new survival data for...

Condition known as benign prostatic hyperplasia common in older men SILVER SPRING, Md., March 2 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The most common symptoms of BPH include a weak stream...